The Phase 3 results for ocedurenone come less than nine months after Novo Nordisk acquired the drug from KBP Biosciences. Novo Nordisk has stopped the clinical trial in uncontrolled hypertension and chronic kidney disease, but is evaluating potential applications of the small molecule in other indications.
The post Novo Nordisk Drug Fails Pivotal Test in Hypertension and Chronic Kidney Disease appeared first on MedCity News.
Recent Posts
Categories
Related Articles
Links
When is a public health problem a crisis? LA has the worst...
Remembering Thomas E. Kurtz
By MIKE MAGEE This has been a challenging week for me, but...
Twin Brothers Launch Seen Health with $22M to Provide Culturally-Focused Care for Seniors
Seen Health emerged from stealth on Monday. The company builds on the...
Value-Based Care Is a Four Layer Cake — Why Do We Only Focus on The Icing?
During a recent panel discussion, three healthcare experts discussed reasons why value-based...
Leave a comment